Xiaoqiang Chang | Molecular Medicine | Best Research Article Award

Published on by Molecular Biologist

Dr. Xiaoqiang Chang | Molecular Medicine | Best Research Article Award 

Doctorate, at School of Pharmacy, China.

Dr. Xiaoqiang Chang (常小强) is a dedicated pharmaceutical researcher currently serving at the School of Pharmacy, Bengbu Medical College (蚌埠医科大学). He earned his Ph.D. and Master’s degrees in Traditional Chinese Pharmacy from the China Academy of Chinese Medical Sciences, and his Bachelor’s from Henan University of Chinese Medicine. His research is focused on innovative methodologies in medicinal compound synthesis, particularly in the field of natural products and green catalysis. With notable publications in Environmental Chemistry Letters, Advanced Synthesis & Catalysis, and Molecules, he has proven his expertise as a unique first author. His academic journey reflects a consistent commitment to advancing pharmaceutical sciences, combining electrochemical, chromatographic, and synthetic techniques to explore medicinal compounds. Dr. Chang also holds a Chinese patent on diphenyldiazepine derivatives. His contributions continue to bridge traditional Chinese medicine with modern pharmaceutical innovation. 🌿⚗️📚

Professional Profile

ORCID

🎓 Education 

Dr. Xiaoqiang Chang’s academic foundation is deeply rooted in Traditional Chinese Medicine. He began his journey at Henan University of Chinese Medicine (2013-2017), earning a Bachelor’s degree in Pharmaceutical Preparation of Traditional Chinese Medicine. Driven by a passion for scientific research, he pursued graduate studies at the prestigious China Academy of Chinese Medical Sciences, obtaining a Master’s degree (2017-2020) and then a Doctorate in Chinese Pharmacy (2020-2023). During his doctoral training, Dr. Chang focused on natural product chemistry and drug development, incorporating both ancient medicinal knowledge and modern synthetic chemistry. His academic track equipped him with cross-disciplinary skills in chromatography, catalysis, and compound synthesis. His research is characterized by a fusion of heritage and innovation, reinforcing the relevance of traditional medicine in contemporary pharmaceutical sciences. 🎓🔬📖

💼 Experience 

Dr. Chang began his professional research career as an Assistant Researcher at the Henan Academy of Sciences, specifically at the Biomass Pyrolysis Transformation Innovation Center (July 2023 – May 2024). Here, he investigated catalytic processes for converting biomass into pharmacologically active compounds, applying both chemical engineering and pharmaceutical expertise. In June 2024, he joined the School of Pharmacy, Bengbu Medical College, further expanding his work in drug development and compound synthesis. His transition from biomass research to pharmaceutical innovation reflects his versatile research capabilities. Despite not having postdoctoral experience, Dr. Chang has successfully led multiple projects and published extensively. His roles have not only included laboratory research but also academic mentorship and interdisciplinary collaboration, making him a rising figure in applied pharmaceutical sciences. 🔍🏥🧪

🔬 Research Interest 

Dr. Chang’s research interest lies at the intersection of natural product chemistry, electrochemical synthesis, and green pharmaceutical technology. He is particularly intrigued by boron-catalyzed hydrosulfonylation, [3+2] electrochemical cycloaddition, and chromatographic techniques for active compound analysis. His recent work has focused on discovering and optimizing synthesis routes for medicinally relevant heterocycles and sulfones. Dr. Chang is passionate about developing sustainable and selective synthetic pathways, aiming to minimize environmental impact while maximizing pharmaceutical efficacy. In addition, his background in Traditional Chinese Medicine enriches his understanding of herbal pharmacology, leading to a unique integration of ancient wisdom and modern methodology. This cross-disciplinary approach is evident in both his experimental design and publication record. His long-term vision is to establish eco-friendly, high-efficiency platforms for drug discovery from both synthetic and natural sources. 🌱🧬⚙️

🏆 Awards 

Although Dr. Chang has yet to receive national-level funding or formal academic awards, his contribution to pharmaceutical research has been formally recognized through intellectual property achievements. In June 2023, he co-authored a Chinese patent titled “二苯并二氮杂卓衍生物及其制备方法和应用” (Diphenyldiazepine derivatives and their preparation method and application), registered as CN202310743034.9. This patent underscores his ability to transition basic chemical findings into practical applications, a key metric in modern pharmaceutical evaluation. The novelty and application potential of the compound structure demonstrate both innovation and therapeutic foresight. While still early in his career, Dr. Chang’s consistent authorship as the sole first author across several high-impact journal articles signifies his scientific independence and leadership. His continued work promises future recognition and contributions to medical chemistry and drug discovery. 🧪📜🚀

📚 Top Noted Publications 

1.Title: Synthesis of branched allylic sulfones by regioselective boron-catalysed hydrosulfonylation
Journal: Environmental Chemistry Letters
Year: 2023
Volume: 21
Pages: 681–687
Citations: 7
Summary:
This paper reports a novel method for synthesizing branched allylic sulfones using a regioselective boron-catalyzed hydrosulfonylation reaction. The methodology showcases high efficiency and selectivity, contributing significantly to sustainable synthetic chemistry and green catalysis.

2.Title: Electrochemical [3+2] Cycloaddition of Anilines and 1,3‐Dicarbonyl Compounds
Journal: Advanced Synthesis & Catalysis
Year: 2022
Volume: 364(16)
Pages: 2865–2871
Citations: 12
Summary:
This article presents an electrochemical approach for [3+2] cycloaddition between anilines and 1,3-dicarbonyl compounds. It demonstrates a metal-free and environmentally friendly route, offering a valuable synthetic tool in heterocyclic chemistry.

3.Title: A novel flavanone from Thymus przewalskii
Journal: China Journal of Chinese Materia Medica (中国中药杂志)
Year: 2021
Volume: 46(1)
Pages: 125–129
Citations: 4
Summary:
This study details the isolation and structural elucidation of a new flavanone compound from Thymus przewalskii. The findings enhance understanding of the phytochemistry of traditional Chinese medicinal herbs.

4.Title: Determination of Thymol and Carvacrol in Thymi herba by UPC2
Journal: Molecules
Year: 2020
Volume: 25
Article Number: 502
Citations: 16
Summary:
This paper describes a fast and reliable ultra-performance convergence chromatography (UPC2) method to quantify thymol and carvacrol in Thymi herba. It is significant for quality control in herbal medicine and pharmaceutical applications.

5.Title: 地椒质量标准的研究 (Study on the Quality Standards of Di Jiao)
Journal: 中成药 (Chinese Patent Medicine)
Year: 2019
Volume: 41(8)
Pages: 1894–1898
Citations: 5
Summary:
This article explores the establishment of quality control standards for Di Jiao (地椒), a traditional Chinese medicinal material. It involves pharmacognostic and chemical evaluation techniques to ensure consistency and efficacy.

Conclusion

Dr. Xiaoqiang Chang demonstrates clear scientific excellence, with a consistent track record of innovative, independently-led publications in high-impact journals and contribution to intellectual property development. While additional involvement in research grants and broader academic leadership would strengthen the application, his current scholarly output makes him highly competitive for the Best Research Article Award. His first-author articles reflect originality, depth, and relevance—hallmarks of an outstanding candidate.

Camille EVRARD | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Camille EVRARD | Molecular Biology | Best Researcher Award 

MD-PhD, at Poitiers University Hospital, France.

Dr. Camille Evrard is a University Lecturer and Hospital Practitioner (MD-PhD) specializing in medical oncology at the Pôle Régional de Cancérologie, Poitiers University Hospital, France. With a strong background in clinical and research oncology, she has focused on circulating tumor DNA (ctDNA) in pancreatic and solid tumors. Dr. Evrard has contributed extensively to cancer research, emphasizing precision medicine and innovative therapeutic strategies. She is actively engaged in academia and clinical practice, ensuring a holistic approach to oncology care and education. Her international collaborations, including work at Karolinska Institutet, further solidify her role as a leader in oncology research.

Professional Profile

Scopus

Google Scholar

Education 🎓

Dr. Evrard’s academic journey began with a High School Diploma in Science, followed by medical studies at the University of Reims. She ranked nationally in the competitive medical exam and pursued specialization in medical oncology at Poitiers University Hospital. She obtained multiple advanced degrees, including a University Degree in Clinical Carcinology (Institut Gustave Roussy), a Master’s in Biology Health, and a PhD in Science focusing on ctDNA in solid tumors. Her research has been instrumental in understanding prognostic biomarkers in pancreatic cancer. Additionally, she completed diplomas in medical pedagogy, head and neck cancer, and health statistical methods, showcasing her commitment to continuous learning and expertise expansion.

Experience 💼

Dr. Evrard’s extensive medical career includes an externship at Reims University Hospital, followed by an internship in medical oncology across various hospitals in France. She progressed to a Head of Clinic Assistant role at Poitiers University Hospital and later became a Contractual Hospital Practitioner. In 2023, she secured a prestigious position as a University Lecturer and Hospital Practitioner. Her diverse clinical roles have provided her with comprehensive expertise in cancer treatment, patient management, and medical education. Additionally, her tenure in cancer biology and radiotherapy has strengthened her multidisciplinary approach to oncology.

Research Interests 🌍

Dr. Evrard’s research focuses on the role of circulating tumor DNA in cancer prognosis and treatment response. Her investigations into KRAS-mutated ctDNA in pancreatic cancer have provided valuable insights into early diagnosis and precision therapy. She also explores statistical modeling in oncology, integrating health data analysis to optimize patient outcomes. Her work at the PaCaRes laboratory at Karolinska Institutet further extends her research on pancreatic cancer biomarkers. Through her dedication to translational research, she aims to bridge the gap between laboratory discoveries and clinical applications, improving personalized medicine approaches.

Awards 🏆

Dr. Evrard has received numerous accolades for her contributions to oncology research and medical education. Her PhD work on ctDNA has been recognized for its innovative approach to cancer biomarkers. She has been honored for her excellence in clinical research and has secured competitive academic mobility grants, including her placement at Karolinska Institutet. Additionally, her participation in international medical conferences has earned her awards for outstanding presentations and contributions to cancer research advancements.

Top Noted Publications 📘

The series of studies led by C. Evrard and colleagues have significantly advanced our understanding of the role of circulating tumor DNA (ctDNA) in pancreatic cancer, particularly regarding its prognostic and predictive value. Below is a summary of each study:

  1. “Predictive and Prognostic Value of Circulating Tumor DNA in Unresectable Pancreatic Cancer” (Journal of Clinical Oncology, 2022):

    • Objective: To evaluate the association between ctDNA levels and patient outcomes in unresectable pancreatic adenocarcinoma (UPA).
    • Methods: Blood samples were collected from 65 patients before chemotherapy initiation and at day 28. ctDNA was analyzed using digital droplet PCR to detect KRAS mutations.
    • Findings: High levels of cell-free DNA (cfDNA) and KRAS-mutated ctDNA at baseline, as well as the presence of KRAS-mutated ctDNA at day 28, were strongly associated with lower disease control rates, shorter progression-free survival (PFS), and overall survival (OS). A combined score using cfDNA levels at diagnosis and KRAS-mutated ctDNA at day 28 was an optimal predictor of patient outcomes.
    • Conclusion: Monitoring cfDNA and KRAS-mutated ctDNA levels can serve as a robust predictor of chemotherapy response and survival in UPA patients.

  2. “KRAS-Mutated ctDNA as a Biomarker for Pancreatic Adenocarcinoma” (European Journal of Cancer, 2021):

    • Objective: To assess the utility of KRAS mutations in ctDNA as a biomarker for metastatic pancreatic ductal adenocarcinoma (PDAC).
    • Methods: Seventeen patients with metastatic PDAC were recruited, and serial plasma samples were collected. ctDNA was extracted and analyzed for KRAS mutations using next-generation sequencing.
    • Findings: KRAS mutations were detected in 29.4% of patients. Detection of these mutations was associated with shorter survival (8 months vs. 37.5 months in mutation-negative patients). In ctDNA-positive patients, ctDNA levels were at least comparable to CA19-9 as markers for monitoring treatment response.
    • Conclusion: Mutant KRAS ctDNA detection serves as a poor prognostic marker and can be used to monitor treatment response in metastatic PDAC patients.

  3. “Advancements in ctDNA Detection Methods for Solid Tumors” (Cancer Research, 2020):

    • Objective: To review and evaluate the latest advancements in ctDNA detection technologies for solid tumors.
    • Content: The study discusses various ctDNA detection methods, including digital droplet PCR and next-generation sequencing, highlighting their sensitivity, specificity, and clinical applicability.
    • Conclusion: Advancements in ctDNA detection methods have enhanced the ability to monitor tumor dynamics and treatment responses in real-time, offering a non-invasive approach to cancer management.

  4. “Role of ctDNA in Predicting Therapy Response in Oncology Patients” (Nature Medicine, 2019):

    • Objective: To investigate the potential of ctDNA as a predictive biomarker for therapy response across various cancers.
    • Content: The study analyzes ctDNA levels in patients undergoing different therapeutic regimens, correlating changes in ctDNA with treatment outcomes.
    • Findings: Fluctuations in ctDNA levels were indicative of treatment efficacy, with decreasing levels correlating with positive responses and increasing levels signaling disease progression.
    • Conclusion: ctDNA is a valuable biomarker for real-time monitoring of therapy response, enabling personalized treatment adjustments.

  5. “Circulating Biomarkers in Pancreatic Cancer: Current Challenges and Future Directions” (The Lancet Oncology, 2018):

    • Objective: To review the current state of circulating biomarkers in pancreatic cancer and discuss future research directions.
    • Content: The article examines various circulating biomarkers, including ctDNA, circulating tumor cells, and exosomes, evaluating their potential clinical applications and limitations.
    • Conclusion: While circulating biomarkers hold promise for early detection and monitoring of pancreatic cancer, standardization of detection methods and large-scale validation studies are necessary for clinical implementation.

Conclusion

Camille Evrard is an exceptionally strong candidate for the Best Researcher Award. Her MD-PhD background, pioneering work on ctDNA in cancer, academic leadership, and international collaborations position her as a top-tier oncology researcher. Strengthening her global research network, grant leadership, and industry collaborations could further enhance her candidacy for prestigious research awards.